Bayer seeks wider use for eye drug Eylea in Europe
Last Updated: Thursday, November 07, 2013, 19:04

Frankfurt: German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.

Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.

The injection, which Bayer is co-developing with Regeneron, is already approved for other eye diseases. ($1 = 0.7392 euros).


First Published: Thursday, November 07, 2013, 19:04

comments powered by Disqus